Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Femasys (FEMY)
NASDAQ:FEMY
Holding FEMY?
Track your performance easily
FEMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.73 - $2.40
Previous CloseN/A
Volume25.00K
Average Volume (3M)137.43K
Market Cap
$25.42M
Enterprise Value$24.30M
Total Cash (Recent Filing)$7.41M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta-1.58
Next Earnings
Mar 27, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding22,898,468
10 Day Avg. Volume88,373
30 Day Avg. Volume137,431
Standard Deviation0.94
R-Squared0.02
Alpha0.10
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20.33
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue18.81
Enterprise Value/Gross Profit35.13
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$8.25Price Target Upside643.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Femasys News
PremiumCompany Announcements
Femasys Advances in Women’s Health InnovationBulls Say, Bears Say
Bulls Say
Initial Sales PerformanceInitial sales of FemaSeed were higher than initial estimates, showcasing positive initial launch efforts.
Partnerships And Market ExpansionThe partnership with Boston IVF will enable the roll-out of FemaSeed to 30 centers within its network of locations in the U.S.
Regulatory ApprovalsThe company has received the European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for FemaSeed, FemVue, FemCerv, and FemCath, providing regulatory approval to begin marketing these products in the European Union.
Bears Say
DilutionThe lower price target reflects a higher projected future share count as modeled future capital raises are expected to be more dilutive due to the decline in share price.
Financial PerformanceThe company ended the quarter with cash and equivalents of $13.5 million compared to $21.7 million at the end of the previous fiscal year.
Risks And CompetitionRisks include safety signals, lower-than-expected efficacy from clinical programs, greater-than-expected commercial competition, regulatory concerns, and financing requirements for the business.
---
Ownership Overview
5.39%
Insiders
1.62% Mutual Funds
1.08% Other Institutional Investors
88.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
FEMY FAQ
What was Femasys’s price range in the past 12 months?
Femasys lowest stock price was $0.73 and its highest was $2.40 in the past 12 months.
What is Femasys’s market cap?
Femasys’s market cap is $25.42M.
When is Femasys’s upcoming earnings report date?
Femasys’s upcoming earnings report date is Mar 27, 2025 which is in 64 days.
How were Femasys’s earnings last quarter?
Femasys released its earnings results on Nov 12, 2024. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.04.
Is Femasys overvalued?
According to Wall Street analysts Femasys’s price is currently Undervalued.
Does Femasys pay dividends?
Femasys does not currently pay dividends.
What is Femasys’s EPS estimate?
Femasys’s EPS estimate is -0.18.
How many shares outstanding does Femasys have?
Femasys has 22,898,468 shares outstanding.
What happened to Femasys’s price movement after its last earnings report?
Femasys reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went down -11.207%.
Which hedge fund is a major shareholder of Femasys?
Currently, no hedge funds are holding shares in FEMY
---
Company Description
Femasys
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. Its mission is to provide women with minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
---
FEMY Stock 12 Month Forecast
Average Price Target
$8.25
▲(643.24% Upside)
Technical Analysis
Mediwound
―
Viveve Medical
―
Myomo
―
Better Therapeutics, Inc.
―
Eloxx Pharmaceuticals
―
Kala Pharmaceuticals
―
Best Analysts Covering FEMY
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+18.01%
reiterated a buy rating 2 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +18.01% per trade.
---